Coadministration of (-)-OSU6162 with l-DOPA normalizes preproenkephalin mRNA expression in the sensorimotor striatum of primates with unilateral 6-OHDA lesions. 2001

W Pirker, and J Tedroff, and H Pontén, and L Gunne, and P E Andrén, and Y L Hurd
Department of Clinical Neuroscience, Karolinska Hospital, Stockholm, S-17176, Sweden.

The substituted phenylpiperidine (-)-OSU6162 is a novel modulator of the dopaminergic systems with low affinity for dopamine D(2) receptors and potent normalizing effects on l-DOPA-induced dyskinesias. We studied the effects of coadministration of (-)-OSU6162 with l-DOPA on the regulation of striatal preproenkephalin (PPE) and prodynorphin (PDyn) mRNA expression in the primate brain by in situ hybridization histochemistry. Common marmoset monkeys sustaining unilateral 6-hydroxydopamine lesions of the nigrostriatal pathway received l-DOPA/carbidopa, l-DOPA/carbidopa plus (-)-OSU6162, or vehicle over 14 days. In vehicle-treated animals, PPE mRNA levels were markedly increased in the sensorimotor territory of the lesioned striatum. By contrast, a rather uniform lesion-induced reduction of PDyn mRNA levels was found in the vehicle group. Subchronic l-DOPA treatment induced a further increase in PPE mRNA expression in a number of sensorimotor and associative subregions of the denervated striatum. Coadministration of (-)-OSU6162 with l-DOPA partially reversed the lesion- and l-DOPA-induced elevation of PPE expression and, by affecting PPE mRNA expression differentially on the intact and lesioned striatum, markedly reduced the side-to-side difference in PPE mRNA expression. The effects on PPE mRNA expression were apparent throughout the rostrocaudal extent of the putamen and the dorsal portions of the caudate nucleus. l-DOPA treatment resulted in an enhancement in PDyn mRNA expression in all functional compartments of the striatum. Coadministration of (-)-OSU6162 had no apparent influence on these l-DOPA-induced changes in PDyn mRNA expression. The present results suggest that (-)-OSU6162 acts primarily by modifying striatal output via the indirect pathway.

UI MeSH Term Description Entries
D007279 Injections, Subcutaneous Forceful administration under the skin of liquid medication, nutrient, or other fluid through a hollow needle piercing the skin. Subcutaneous Injections,Injection, Subcutaneous,Subcutaneous Injection
D007980 Levodopa The naturally occurring form of DIHYDROXYPHENYLALANINE and the immediate precursor of DOPAMINE. Unlike dopamine itself, it can be taken orally and crosses the blood-brain barrier. It is rapidly taken up by dopaminergic neurons and converted to DOPAMINE. It is used for the treatment of PARKINSONIAN DISORDERS and is usually given with agents that inhibit its conversion to dopamine outside of the central nervous system. L-Dopa,3-Hydroxy-L-tyrosine,Dopaflex,Dopar,L-3,4-Dihydroxyphenylalanine,Larodopa,Levopa,3 Hydroxy L tyrosine,L 3,4 Dihydroxyphenylalanine,L Dopa
D008024 Ligands A molecule that binds to another molecule, used especially to refer to a small molecule that binds specifically to a larger molecule, e.g., an antigen binding to an antibody, a hormone or neurotransmitter binding to a receptor, or a substrate or allosteric effector binding to an enzyme. Ligands are also molecules that donate or accept a pair of electrons to form a coordinate covalent bond with the central metal atom of a coordination complex. (From Dorland, 27th ed) Ligand
D008297 Male Males
D010302 Parkinson Disease, Secondary Conditions which feature clinical manifestations resembling primary Parkinson disease that are caused by a known or suspected condition. Examples include parkinsonism caused by vascular injury, drugs, trauma, toxin exposure, neoplasms, infections and degenerative or hereditary conditions. Clinical features may include bradykinesia, rigidity, parkinsonian gait, and masked facies. In general, tremor is less prominent in secondary parkinsonism than in the primary form. (From Joynt, Clinical Neurology, 1998, Ch38, pp39-42) Atherosclerotic Parkinsonism,Secondary Parkinsonism,Symptomatic Parkinson Disease,Parkinson Disease, Secondary Vascular,Parkinson Disease, Symptomatic,Parkinsonism, Secondary,Parkinsonism, Symptomatic,Secondary Vascular Parkinson Disease,Parkinsonism, Atherosclerotic,Secondary Parkinson Disease,Symptomatic Parkinsonism
D010880 Piperidines A family of hexahydropyridines.
D011498 Protein Precursors Precursors, Protein
D011699 Putamen The largest and most lateral of the BASAL GANGLIA lying between the lateral medullary lamina of the GLOBUS PALLIDUS and the EXTERNAL CAPSULE. It is part of the neostriatum and forms part of the LENTIFORM NUCLEUS along with the GLOBUS PALLIDUS. Nucleus Putamen,Nucleus Putamens,Putamen, Nucleus,Putamens,Putamens, Nucleus
D002144 Callithrix A genus of the subfamily CALLITRICHINAE occurring in forests of Brazil and Bolivia and containing seventeen species. Callithrix jacchus,Hapale,Marmoset, Common,Marmoset, Short-Tusked,Marmosets,Common Marmoset,Common Marmosets,Marmoset,Marmoset, Short Tusked,Short-Tusked Marmoset,Short-Tusked Marmosets
D002421 Caudate Nucleus Elongated gray mass of the neostriatum located adjacent to the lateral ventricle of the brain. Caudatus,Nucleus Caudatus,Caudatus, Nucleus,Nucleus, Caudate

Related Publications

W Pirker, and J Tedroff, and H Pontén, and L Gunne, and P E Andrén, and Y L Hurd
December 2002, The European journal of neuroscience,
W Pirker, and J Tedroff, and H Pontén, and L Gunne, and P E Andrén, and Y L Hurd
February 2000, European journal of pharmacology,
W Pirker, and J Tedroff, and H Pontén, and L Gunne, and P E Andrén, and Y L Hurd
February 2012, Brain research bulletin,
W Pirker, and J Tedroff, and H Pontén, and L Gunne, and P E Andrén, and Y L Hurd
February 1999, Experimental neurology,
W Pirker, and J Tedroff, and H Pontén, and L Gunne, and P E Andrén, and Y L Hurd
May 2001, Neuroreport,
W Pirker, and J Tedroff, and H Pontén, and L Gunne, and P E Andrén, and Y L Hurd
June 2016, Neuroscience,
W Pirker, and J Tedroff, and H Pontén, and L Gunne, and P E Andrén, and Y L Hurd
April 1995, Brain research. Molecular brain research,
W Pirker, and J Tedroff, and H Pontén, and L Gunne, and P E Andrén, and Y L Hurd
October 1995, Neuroscience,
W Pirker, and J Tedroff, and H Pontén, and L Gunne, and P E Andrén, and Y L Hurd
January 2013, European journal of pharmacology,
W Pirker, and J Tedroff, and H Pontén, and L Gunne, and P E Andrén, and Y L Hurd
March 2012, Journal of neurochemistry,
Copied contents to your clipboard!